Metformin in SARS-CoV-2 infection

• Autor(a) principal: Pedrosa, Ana Realista
• Data de Publicação: 2023
• Outros Autores: Martins, Diana Cruz, Rizzo, Manfredi, Silva-Nunes, José
• Tipo de documento: Outros
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/151470
• topic: COVID-19; Diabetes; Metformin; Mortality; SARS-CoV-2; Severity; Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology; SDG 3 - Good Health and Well-being

SARS-CoV-2 infection has been a major threat to human health and a huge challenge to Medicine. In only two years, COVID-19 affected >350 million people, causing >5.6 million deaths. Chronic inflammatory states, such as diabetes or obesity, are known risk factors for COVID-19 poorest outcomes, with higher risk for disease severity and greater mortality. Metformin remains on the first line of the management of hyperglycemia in type 2 diabetes. Through its anti-inflammatory and immunomodulatory mechanisms, metformin appears as an opportunity to control the dysregulated cytokine storm secondary to SARS-CoV-2 infection. Recent studies point towards a potential protective role of metformin in the course of COVID-19, showing that current or previous treatment with metformin associates with better outcomes.